Cingulate (CINGW) Cash from Investing Activities (2021 - 2025)
Cingulate's (CINGW) quarterly Cash from Investing Activities came in at -$156213.0 in Q4 2025, up 21.29% on a YoY basis from -$128794.9 in Q4 2024, and up 21.29% quarter-over-quarter from -$198462.0 in Q4 2024.
Powered by 
Analysis
Cingulate (CINGW) Cash from Investing Activities (2021 - 2025) Analysis & Trends
Cingulate (CINGW) has reported Cash from Investing Activities for 5 consecutive years, with -$156213.0 the latest figure, recorded in Q4 2025.
- For the quarter ending Q4 2025, Cash from Investing Activities rose 21.29% year-over-year to -$156213.0; the trailing twelve-month figure through Dec 2025 stood at -$213880.0 (down 0.98% YoY), and the FY2025 full-year result was -$162138.0, up 23.45% from the prior year.
- Cash from Investing Activities grew to -$156213.0 in Q4 2025 per CINGW's latest filing, from -$198462.0 in the prior quarter.
- Across five years, Cash from Investing Activities topped out at $140795.0 in Q3 2024 and bottomed at -$710007.0 in Q4 2021.
- Historically, Cash from Investing Activities has averaged -$97468.6 across 5 years, with a median of -$51802.0 in 2021.
- The sharpest annual moves came in 2022 and 2024: Cash from Investing Activities surged 120.6% in 2022, then tumbled 7262400.0% in 2024.
- Over 5 years, Cash from Investing Activities stood at -$710007.0 in 2021, then jumped by 79.86% to -$143020.0 in 2022, then sank by 30.72% to -$186960.0 in 2023, then declined by 6.15% to -$198462.0 in 2024, then increased by 21.29% to -$156213.0 in 2025.
- According to Business Quant data, Cash from Investing Activities over the past three periods registered -$156213.0, -$198462.0, and $140795.0 for Q4 2025, Q4 2024, and Q3 2024 respectively.
Peer Set
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Cash from Investing Activities (Qtr) |
|---|---|---|---|---|---|
| 1 | Johnson & Johnson | 646.24 Bn | 625.48 Bn | 17.26 Bn | -1.11 Bn |
| 2 | AbbVie | 441.52 Bn | 434.96 Bn | 12.70 Bn | -1.20 Bn |
| 3 | Merck | 365.75 Bn | 358.60 Bn | 12.21 Bn | -5.60 Bn |
| 4 | Novartis Ag | 266.61 Bn | 258.92 Bn | 11.24 Bn | -3.11 Bn |
| 5 | Pfizer | 159.09 Bn | 147.39 Bn | 10.94 Bn | 2.11 Bn |
| 6 | Sanofi | 52.43 Bn | 45.05 Bn | 10.79 Bn | -424.26 Mn |
| 7 | Revolution Medicines | 44.04 Bn | 44.04 Bn | - | -1.66 Bn |
| 8 | Incyte | 25.32 Bn | 20.79 Bn | 1.57 Bn | -51.79 Mn |
| 9 | United Therapeutics | 21.43 Bn | 18.77 Bn | 683.80 Mn | 87.50 Mn |
| 10 | Cingulate | 100,214.03 | 100,214.03 | - | - |
Historic Data
Download Data
Historic Data
| Date | Value |
|---|---|
| Dec 31, 2025 | -156,213.00 |
| Dec 31, 2024 | -198,462.00 |
| Sep 30, 2024 | 140,795.00 |
| Jun 30, 2024 | -72,625.00 |
| Mar 31, 2024 | -81,508.00 |
| Dec 31, 2023 | -186,960.00 |
| Jun 30, 2023 | -1.00 |
| Mar 31, 2023 | -37,135.00 |
| Dec 31, 2022 | -143,020.00 |
| Sep 30, 2022 | 3,250.00 |
| Jun 30, 2022 | -2,482.00 |
| Mar 31, 2022 | -10,400.00 |
| Dec 31, 2021 | -710,007.00 |
| Sep 30, 2021 | -15,774.00 |
| Jun 30, 2021 | -22,486.00 |
| Mar 31, 2021 | -66,469.00 |